Who is the Owner of Johnson and Johnson

Top 5 Johnson & Johnson Shareholders (JNJ)

The Johnson & Johnson Group ( NYSE: JNJ) is one of the oldest and most respected U.S. corporations still in existence today. Created in 1886 by the three Johnson brothers Robert, James and Edward, the firm was based in New Brunswick, New Jersey. As Johnson & Johnson has evolved over its long career, the firm remains an important innovator and healthcare forerunner.

It was the first to standardise and mass-produce first aids kit, motherhood kit, women's product and oral care before 1900. A Missouri panel of judges on July 12, 2018, ordered the corporation to disburse $4.69 billion to 22 females who alleged the company's talcum-based drugs, include its infant formula, to contain and cause ovary cancers.

The number of outstanding Johnson and Johnson claims is continuing to grow, according to the company's 2017 financial year. However, the firm disputes that its talcum derivatives cause cancers and that they have ever included them. The five most important single Johnson and Johnson stockholders are listed below. Alex Gorsky, COO and Chair of the Johnson & Johnson Boards of directors, is the principal single stockholder.

Effective February 27, 2018, Gorsky 2. Born in 1988, Gorsky came to JNJ as a commercial agent and was promoted by the family. Until 2003, he was appointed CEO of JNJ's pharmaceuticals group and CEO of Janssen Pharmaceuticals, a JNJ affiliate. Gorsky, however, retired from JNJ in 2004 after being appointed Head of the Pharmaceuticals Division of Novartis AG (NYSE: NVS).

Gorsky briefly worked at Novartis before returning to JNJ in 2008 as Group Leader for Ethicon Inc. Until 2013, Gorsky was appointed Chief Executive Officer and President of JNJ, where he remains active. JNJ's second single major stockholder is Dominic Caruso with 1.26 million common stock, according to the company's most recent SEC application dated February 27, 2018.

In 1999, Caruso joined JNJ after acquiring the healthcare firm Centocor Inc., where he was the Senior VP of finance. Caruso has been JNJ's Deputy Chairman of Group Finance since 2005. Caruso was appointed in 2007 as CFO and EVP.

In 2018, he will continue as CFO and Execution VP of Finance. With 624,456 outstanding as of February 27, 2018, Joaquin Duato is JNJ's third biggest single stockholder. He is currently Duato's current Senior VP and Global Spokesman, Pharma, a post he has occupied since 2011.

Mr. Becker has been with the firm for almost three decades. to date. Dr. Paulus Stoffels is JNJ's forth biggest single stockholder with 202,564 outstanding JNJ stock as of February 2018. Mr. Stoffeels has been JNJ's CEO since October 2012 and was appointed to the position of JNJ's Senior VP in May 2016. Dr. Stoffels is also the JNJ Director of Research and R&D for Pharmaceuticals.

Sandra Peterson held 454,791 JNJ stock as of February 27, 2018, making her the fifth biggest single stockholder. He is the company's global group president and is in charge of Johnson & Johnson's consumption and healthcare business. Peterson was previously CEO and President of Bayer CropScience AG in Germany before moving to Johnson & Johnson.

In addition, she was CEO of Bayer Medical Care and Chairman of the Diabetes Care Division of Bayer HealthCare AG. Prior to that, she was with Medco Health Solutions, Nabisco, Whirlpool Corporation and McKinsey & Company.